Recent advancements in cancer research, as published in NatureMedicine, have highlighted the potential of personalized immunotherapy treatments, focusing on the genetic mutations in tumor cells and the role of the microbiome in cancer therapy. Researchers from MIT, Dana-Farber Cancer Institute, Harvard Medical School, and other institutions, including LawleyLab, sangerinstitute, and ONJCRI, have developed a platform to identify genetic mutations that could widen access to these treatments. Additionally, insights into the microbiome have shown that gut bacteria can indicate the likelihood of a patient benefiting from combination immunotherapy for rare cancers. This research could lead to the development of probiotics that support cancer therapy by modulating the microbiome.
Recent review underscores importance of leveraging T-cell repertoire to unlock its potential to understand immune responses and disease mechanisms, particularly in cancer research. Learn more about Omniscope’s solutions here: https://t.co/b4ATGKWrJE 🗞️ https://t.co/mX6ZvY8JRp https://t.co/AVRouik5p4
How knowing the gut microbiome constituents can promote success of immunotherapy for cancer https://t.co/oGUZr7v37o @NatureMedicine @LawleyLab
Efforts to identify microbial signatures of response to immune checkpoint blockade suggest that strain-level associations may be cancer type-agnostic, but cancer therapy-specific https://t.co/eNBG5L2vQK
Someone’s gut bacteria can show if they would benefit from combination immunotherapy for multiple rare cancers. 🧫 This could help develop probiotics that modulate the #microbiome to support #cancer therapy from the inside. 💊⤵️ https://t.co/0Odd3cxL0Y
It is an honour to share our @LawleyLab @sangerinstitute @ONJCRI work describing a high-resolution microbiome signature for combo immune checkpoint blockade (CICB) response, published today in @NatureMedicine! https://t.co/h7QjzBrWx9 A 🧵...
New microbiome insights could help boost #immunotherapy for a range of rare cancers @NatureMedicine https://t.co/KCKc0l1VlZ
A new research study from scientists at MIT, Dana-Farber Cancer Institute, Harvard Medical School, and elsewhere explains one of the mechanisms that potentially cancerous mutations use to evade the immune system. Learn more: https://t.co/q2HKQCjnk4 https://t.co/QmoeieQG5d
Cancer Platform Could Widen Immunotherapy Access Researchers have developed a platform to identify genetic mutations in tumor cells that could widen access to personalized immunotherapy treatments for cancer. Learn more: https://t.co/QDlYSudsO3 https://t.co/vOo6zs4wqh